{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:55:23Z","timestamp":1768341323742,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.thromres.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:24:35Z","timestamp":1684977875000},"page":"128-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Arterial events in cancer patients treated with apixaban for venous thrombosis"],"prefix":"10.1016","volume":"228","author":[{"given":"Trine-Lise","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marte","family":"Svalastoga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorunn","family":"Brekke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tone","family":"Enden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege","family":"Fr\u00f8en","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herish","family":"Garresori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Marie","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petter Quist","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina Carmen","family":"Porojnicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Hansen","family":"Ree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dag","family":"Torfoss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin Osvik","family":"Velle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde Skuterud","family":"Wik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per Morten","family":"Sandset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders Erik Astrup","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.thromres.2023.05.017_bb0005","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2023.05.017_bb0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncol."},{"issue":"2","key":"10.1016\/j.thromres.2023.05.017_bb0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaccao.2021.02.007","article-title":"Arterial thromboembolism in cancer patients: a Danish population-based cohort study","volume":"3","author":"Mulder","year":"2021","journal-title":"JACC CardioOncol."},{"issue":"3","key":"10.1016\/j.thromres.2023.05.017_bb0020","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.mayocp.2020.05.045","article-title":"Incidence and risk of various types of arterial thromboembolism in patients with cancer","volume":"96","author":"Wang","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.thromres.2023.05.017_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2019.10.004","article-title":"Frequency of arterial thromboembolism in populations with malignancies: a systematic review","volume":"184","author":"Yu","year":"2019","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.thromres.2023.05.017_bb0030","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010133","article-title":"Higher stroke incidence in the patients with pancreatic cancer: a nation-based cohort study in Taiwan","volume":"97","author":"Chan","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1, Cerebrovascular Disease","key":"10.1016\/j.thromres.2023.05.017_bb0035","first-page":"15","article-title":"Stroke epidemiology and risk factor management","volume":"23","author":"Guzik","year":"2017","journal-title":"Continuum (Minneap. Minn.)"},{"issue":"1","key":"10.1016\/j.thromres.2023.05.017_bb0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2478\/jccm-2021-0002","article-title":"Ischemic stroke in patients with cancer: a retrospective cross-sectional study","volume":"7","author":"Motataianu","year":"2021","journal-title":"J. Crit. Care Med."},{"key":"10.1016\/j.thromres.2023.05.017_bb0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.thromres.2020.08.042","article-title":"Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism","volume":"196","author":"Hannevik","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2023.05.017_bb0050","first-page":"1","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up","author":"Larsen","year":"2022","journal-title":"J. Thromb. Haemos"},{"issue":"5","key":"10.1016\/j.thromres.2023.05.017_bb0055","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2023.05.017_bb0060","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ijrobp.2018.12.011","article-title":"Selection bias in population registry-based comparative effectiveness research","volume":"103","author":"Soni","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.017_bb0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.semradonc.2019.05.011","article-title":"Population-based observational studies in oncology: proceed with caution","volume":"29","author":"Soni","year":"2019","journal-title":"Semin. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2023.05.017_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.thromres.2023.05.017_bb0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"Buxhofer-Ausch","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2023.05.017_bb0080","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.thromres.2021.12.018","article-title":"Neutrophil extracellular traps and cancer-associated thrombosis","volume":"213","author":"Rosell","year":"2022","journal-title":"Thromb. Res."},{"issue":"14","key":"10.1016\/j.thromres.2023.05.017_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143339","article-title":"Neutrophil extracellular traps and pancreatic cancer development: a vicious cycle","volume":"14","author":"Mitsis","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.thromres.2023.05.017_bb0090","first-page":"2701","article-title":"Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials","volume":"20","author":"Liang","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.017_bb0095","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Ando","year":"2020","journal-title":"Investig. New Drugs"},{"issue":"8","key":"10.1016\/j.thromres.2023.05.017_bb0100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"Jama."},{"issue":"7553","key":"10.1016\/j.thromres.2023.05.017_bb0105","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"Bmj."},{"issue":"13","key":"10.1016\/j.thromres.2023.05.017_bb0110","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"Jama."},{"issue":"2","key":"10.1016\/j.thromres.2023.05.017_bb0115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/clpt.2009.108","article-title":"COX-1 and vascular disease","volume":"86","author":"Vanhoutte","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.thromres.2023.05.017_bb0120","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jama.2015.0809","article-title":"Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction","volume":"313","author":"Schjerning Olsen","year":"2015","journal-title":"Jama."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:51:47Z","timestamp":1758736307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823001500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":24,"alternative-id":["S0049384823001500"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.05.017","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arterial events in cancer patients treated with apixaban for venous thrombosis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}